Trine A. Kristiansen

Trine A. Kristiansen

Auto-generated profile, based on publicly available information

Trine A. Kristiansen

Center for Regenerative Medicine, Massachusetts General Hospital

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
TKTrine A. Kristiansen
Trine A. Kristiansen
QZQinyu Zhang
Qinyu Zhang
SVStefano Vergani
Stefano Vergani
EBElena Boldrin
Elena Boldrin
NKNiklas Krausse
Niklas Krausse
JYJoan Yuan
Joan Yuan
The fetal-to-adult switch in hematopoietic stem cell (HSC) behavior is characterized by alterations in lineage output and entry into deep quiescence. Here we identify the emergence of megakaryocyte (Mk)-biased HSCs as an event coinciding with this developmental switch. Single-cell chromatin accessibility analysis reveals a ubiquitous acquisition of Mk lineage priming signatures in HSCs during the fetal-to-adult transition. These molecular changes functionally coincide with increased amplitude of early Mk differentiation events after acute inflammatory insult. Importantly, we identify LIN28B, known for its role in promoting fetal-like self-renewal, as an insulator against the establishment of an Mk-biased HSC pool. LIN28B protein is developmentally silenced in the third week of life, and its prolonged expression delays emergency platelet output in young adult mice. We propose that developmental regulation of Mk priming may represent a switch for HSCs to toggle between prioritizing self-renewal in the fetus and increased host protection in postnatal life.

21 October 2026 in Cell
Verified
Journal Article
Open access
DLDonghui Li
Donghui Li
AIAlberto De Iaco
Alberto De Iaco
KNKevin C. Ngan
Kevin C. Ngan
GSGeorgy Smyshlyaev
Georgy Smyshlyaev
NKNinad Kumbhojkar
Ninad Kumbhojkar
CCCecilia Cotta-Ramusino
Cecilia Cotta-Ramusino
Efficient integration of gene-length cargos in vivo remains challenging. Non-long terminal repeat (non-LTR) retrotransposons, which naturally mobilize large DNA segments through an RNA intermediate, could potentially address these limitations. Here, we developed a computational pipeline to systematically identify a diverse set of non-LTR retrotransposons. Extensive engineering generated elements capable of the efficient and stable insertion of reporter genes in human cells using RNA templates introduced in trans, which we term Gene Writers. Gene Writers successfully generated CD19 and CD20 chimeric antigen receptor T (CAR-T) cells ex vivo with robust antitumor activity. Lipid nanoparticle-mediated RNA delivery enabled in vivo CAR-T cell generation and stable B cell depletion in a humanized mouse model. Our study delineates a comprehensive framework for the discovery, engineering, and application of non-LTR retrotransposons and demonstrates their utility for gene-sized cargo delivery in vivo, thereby bridging a critical gap in existing gene therapy modalities.

5 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
GSGiulia Schiroli
Giulia Schiroli
VKVinay Kartha
Vinay Kartha
FDFabiana M. Duarte
Fabiana M. Duarte
TKTrine A. Kristiansen
Trine A. Kristiansen
CMChristina Mayerhofer
Christina Mayerhofer
DSDavid T. Scadden
David T. Scadden
Hematopoietic stem cell mutations can result in clonal hematopoiesis (CH) but the clinical outcomes are heterogeneous. The nature of the founder mutation and secondary mutations likely drive emergent neoplastic disease. We investigated how the state of the cell of origin where the Tet2 mutation occurs affects susceptibility to that commonly occurring CH mutation. Here, we provide evidence that risk is written in the epigenome of the cell of origin. By characterizing cell states that underlie myeloid differentiation and linking this information to an inducible system to assess myeloid progenitor clones, we provide evidence that epigenetic markers of the cell where Tet2 mutation occurs stratifies clonal behaviors. Specifically, Sox4 fosters a global cell state of high sensitization towards Tet2 KO. Using GMP and primary HSC models, we show that Sox4 promotes cell dedifferentiation, alters cell metabolism and increases the in vivo clonal output of mutant cells. Our results validate the hypothesis that epigenetic features can predispose specific clones for dominance and explain why an identical mutation can result in different outcomes.